Sagility Limited has announced robust financial performance for the year ended March 31, 2026. The company achieved a 29.1% revenue growth, reaching ₹71,929 million for the fiscal year. With an Adjusted EBITDA of 25.3% and significant improvements in profitability, the company continues to solidify its position as a global leader in AI-driven healthcare operations, supported by a growing base of major US-based payer and provider clients.
Fiscal Year 2026 Financial Performance
Sagility delivered strong growth throughout FY26, reporting a total revenue of ₹71,929 million, which marks a 29.1% increase over the previous year. The company’s profitability saw substantial gains, with Adjusted EBITDA rising to ₹18,200 million (a margin of 25.1%) and Adjusted PAT reaching ₹11,306 million, representing a 39.5% growth compared to FY25. Basic earnings per share (EPS) surged by 69.2% to ₹1.98 for the year.
Quarterly Highlights
For the final quarter (Jan-Mar 2026), Sagility reported revenue of ₹20,243 million, a 29.1% year-over-year growth. The quarterly Adjusted EBITDA stood at ₹5,036 million, reflecting the company’s disciplined operational approach. The Board has also announced a final dividend of ₹0.10 per share.
Strategic Business Expansion
The company’s growth is underpinned by key strategic developments, including securing $30.7 million in potential steady-state annual contract value (ACV). During FY26, Sagility added 17 new clients and currently services 82 active client groups. The company has maintained a strong focus on AI integration, advancing its SmarTec and Synchrony suite of solutions to drive smarter end-to-end healthcare operations.
Operational Reach and Future Outlook
As of March 31, 2026, Sagility maintains a global presence across 5 countries with 31 delivery centers and a workforce of 46,860 employees. Management credited the year’s success to disciplined cost management, execution excellence, and a shift toward technology and AI-led healthcare transformation, which has helped the company navigate a complex U.S. healthcare regulatory environment.
Source: BSE
